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ABSTRACT 
Background: Manuka honey is recognized for it’s health-promoting properties and it’s use in 
medicine is well documented. However, the actions of Manuka honey are limited by rapid 
digestion and the inactivation of bioactive components such as methylglyoxal. Cyclodextrins 
are naturally occurring glucose rings that improve stability and bioactivity of products. This 
study  investigates  the  tolerability  and  bioactivity  of  -cyclodextrin-complexed  Manuka 
honey called Manuka Honey with CycloPower 
TM. 
 
Methods:  The  antibacterial  properties  of  Manuka  honey  complexed  with  -cyclodextrin 
(Manuka honey with Cyclopower
TM) were compared to uncomplexed Manuka honey against 
a range of common organisms using standard measurements of minimum inhibitory (MIC) 
and bactericidal (MBC) concentrations. Time course growth measurements were determined 
using a sublethal concentration of 2% w (honey solids)/v and measuring the area under the 
growth curve. 
 
Results: In tube MIC assays, Manuka honey completely inhibited Staphylococcus aureus 
(MSSA and MRSA), Streptococcus pyogenes, Helicobacter pylori and Moraxella catarrhalis 
at  concentrations  of  10%  w/v  or  less,  with  MIC  values  decreasing  as  the  methylglyoxal 
content of the honeys increased from 100 to 550 mg/kg. MIC values at a given methlyglyoxal 
level were also decreased for S. pyogenes, M. catarrhalis and H. pylori by complexing the 
Manuka honey with -cyclodextrin. Pseudomonas aeruginosa was not inhibited by any of 
the  Manuka  honey  or  Cyclopower  treatments  at  the  concentrations  tested  (2-10%  w/v). 
Manuka honey with Cyclopower
TM had an increased bacteriostatic action against S. aureus, 
MRSA and P. aeruginosa compared with Manuka honey.  
 
Conclusions: This study concludes that Manuka honey is an effective antibacterial agent that 
can be enhanced by complexing with -cyclodextrin. 
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INTRODUCTION: 
The use of honey in medicine and to promote health and wellness is well documented [1-3]. 
The first investigations to elucidate the bioactive components of honey identified hydrogen 
peroxide (produced by glucose oxidase) as being the primary antibacterial agent [4], although 
minor  roles  were  assigned  to  osmolarity  and  acidity  [5].  Antibacterial  efficacy  has  been 
demonstrated in vitro with high hydrogen peroxide producing honeys
 [6, 7]. Although their 
usefulness in medicine appears to be limited as glucose oxidase is rapidly broken down by 
heat and light
 [8, 9] and the hydrogen peroxide generated is rapidly degraded by catalase, an 
enzyme present in all body fluids [10]. 
Manuka (Leptospermum scoparium) honey from New Zealand offers potential in health 
and wellness as it contains a stable antimicrobial compound, originally termed “non-peroxide 
activity  (NPA)”,  now  identified  as  methylglyoxal  [11].  Manuka  honeys  with  high 
methylglyoxal levels have potent antibacterial action against a range of bacterial species, 
including those resistant to frontline antibiotics [12-14]. Further, the synergistic action of 
methylglyoxal  with  conventional  antibiotics  has  also  been  demonstrated  [15].  The 
recognition of the medical capabilities of Manuka honey has led to a number of medical 
grade products being produced, these including sterilised honey, skin care products, wound 
dressings and cough lozenges [1, 16, 18]. 
Unfortunately, the oral application of Manuka honey is limited because the sugars in 
honey are rapidly absorbed (approximately 70% of honey by weight is glucose and fructose) 
and methylglyoxal is rapidly degraded via reaction with other food components [19, 20]. To 
circumvent  this,  researchers  have  been  investigating  new  formulations  that  may  offer 
improved  stability  and  efficacy.  One  such  product  is  Manuka  honey  complexed  with 
cyclodextrin,  a  naturally  occurring  cyclical  oligosaccharide  (Manuka  Honey  with 
CycloPower™). This product promises to be easier to handle due to its powdered form, and 
may promote enhanced delivery and slow release of active components to the gastrointestinal 
tract. Cyclodextrins are primarily employed as excipients for the delivery of hydrophobic 
drugs,  improving  water  solubility  and  stability  [21,  22].  The  mode  of  action  involves 
complexation with the drug, which may be via the hydrophobic central cavity of cyclodextrin 
or  through  the  formation  of  non-inclusion  complexes  [22].  Cyclodextrins  are  “generally 
recognized  as  safe”  and  used  in  drug  products  for  oral,  rectal,  topical  and  parenteral 
administration [22]. It is hypothesised that this formulation will retain antibacterial activity 
for  a  longer  period  of  time,  thereby  allowing  for  enhanced  action  against  infections. 
Cyclodextrin may also offer bioactive advantages of its own: 1) as a soluble dietary fibre 
because it is not hydrolyzed by salivary or pancreatic amylase [23, 24]; 2) to yield short-chain 
fatty  acids  due  to  fermentation  by  the  intestinal  microbiota  [25];  and  3)  to  reduce  the 
glycemic  index  of  foods  that  it  is  incorporated  with  [26].  Thus,  the  ingestion  of  -
cyclodextrin-complexed Manuka honey could lead to some of the beneficial physiological 
effects that are typically associated with the intake of fermentable dietary fibres and/or make 
it a more suitable product for diabetic individuals.  
In this study the in vitro antimicrobial efficacy of high methylglyoxal Manuka honeys 
complexed  with  cyclodextrin  (Manuka  Honey  with  CycloPower
TM)  was  tested  in 
comparison to matched (uncomplexed) Manuka honeys against a selection of common Gram-
negative and Gram-positive pathogens.  
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MATERIALS AND METHODS: 
Honey preparations 
Manuka  honey  (MGO™  Manuka  honey),  powdered  Manuka  honey  with  CycloPower™ 
(containing honey with methylglyoxal at minimum levels of 100, 250, 400 and 550 mg/kg), 
and  -cyclodextrin  were  supplied  by  Manuka  Health  New  Zealand  Ltd  (Auckland,  New 
Zealand). MGO™ Manuka honey is 83% honey solids and 17% water; Manuka Honey with 
CycloPower™  is  55%  cyclodextrin  plus  45%  honey  solids.  Matched  samples 
(uncomplexed honey and cyclodextrin-complexed honey with the same methylglyoxal level) 
were re-suspended by weight percent of the honey solids in either sterile water or sterile 
culture broth, containing 0.1% w/v catalase (Sigma Aldrich, Australia).  Catalase was added 
to remove the effect of hydrogen peroxide produced as a result of glucose oxidase activity 
occurring as honey is diluted, thus ensuring that only non-peroxide antibacterial activity was 
being measured [27]. Preparations were sterile filtered prior to dilution, although preliminary 
experiments  with  Staphylococus  aureus  showed that  aseptically prepared honey solutions 
were sterile prior to filtration and that filtration did not affect antibacterial activity. 
 
Bacterial strains 
Antibacterial activity was tested against Enterobacter aerogenes ATCC 13048, Helicobacter 
pylori NCTC 11637, Moraxella catarrhalis ATCC 25238, Pseudomonas aeruginosa ATCC 
27853, Staphylococcus aureus ATCC 6538, Staphylococcus aureus ATCC 33593 (an MRSA 
strain) and Streptococcus pyogenes ATCC 8668. 
 
Bacterial growth conditions 
Overnight broth cultures and antibacterial assays were performed in Brain Heart Infusion 
(BHI)  broth  (Difco)  for  E.  aerogenes,  M.  catarrhalis,  P.  aeruginosa,  S.  aureus  and  S. 
pyogenes. H. pylori was cultured in Brucella broth (Difco) containing 2.5% v/v foetal calf 
serum  (FCS;  Life  Technologies),  antibacterial  assays  were  performed  in  Brucella  broth 
containing a final concentration of 1.25% v/v FCS. Agar plate culture and MBC plate counts 
used horse blood agar for all species except H. pylori (Brucella agar containing 2.5% FCS). 
All cultures were grown at 37
oC. H. pylori was cultured in 90mm Petri dishes containing 
10ml broth or 35mm Petri dishes containing 2-3ml broth in a microaerophilic atmosphere 
generated by a CampyGen gas pack (Oxoid) in a 2.5l gas jar (Oxoid). MacConkey and Eosin 
Methylene Blue (EMB) agar plates were obtained from Fort Richard, Auckland. 
 
Minimum inhibitory concentration (MIC) 
For assay of activity against E. aerogenes, M. catarrhalis, P. aeruginosa, S. aureus and S. 
pyogenes a 20% w (honey solids)/v preparation of MGO™ Manuka honey or Manuka Honey 
with  CycloPower
TM  powder  in  sterile  water  plus  0.1%  w/v  catalase  was  prepared  by 
incubation with shaking at 37
oC for 30 to 60 minutes. The homogenous solution obtained was 
diluted  to  give  a  series  of  concentrations,  which  when  mixed  1:1  with  a  suspension  of 
bacteria at approximately 10
6 CFU/ml in BHI, gave 10, 8, 6, 4, 2, 1 and 0 % w (honey 
solids)/v. Tube assays were performed in 2 ml, microplate assays in 200 . Assays were 
incubated overnight at 37
oC with shaking at 100 rpm for microplates and 200 rpm for tubes. 
Growth was estimated by the measurement of any increase in absorbance at 600 nm using 
either cuvettes  with  a 1 cm  path  length  (Novaspec  II  spectrophotometer), or microplates 
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rather than agar diffusion methods to avoid potential artefacts arising from the slow release of 
methylglyoxal from the Cyclopower
TM complex. 
 
Minimum bactericidal concentration (MBC) 
MIC broths that did not show growth were used to inoculate agar plates (20 l inocula) and 
grown at 37
oC. The viable count of the final inoculum  was compared with the count of 
bacteria remaining at 18-48 h to calculate the MBC, defined as the lowest concentration of 
the honey product giving 99.9% kill of the organism under test.  
 
Testing anti-Helicobacter pylori activity 
As  H.  pylori  is  a  fastidious  organism  requiring  culture  for  a  number  of  days  in  a 
microaerophilic environment a modified methodology was employed. A 48-72 h culture of H. 
pylori in Brucella broth plus 2.5% FCS at an absorbance between 0.5 and 1.0 at 570 nm was 
diluted 1 in 1000 and grown overnight to produce an inoculum at an A570nm around 0.1 and 
containing about 10
5 CFU/ml. The viable count from the inoculum was determined by plating 
a dilution series to Brucella agar + 2.5% FCS. Solutions of MGO™ Manuka honey and 
Manuka Honey with CycloPower
TM were prepared in Brucella broth at 4 and 8% w (honey 
solids)/v. Brucella broth alone was used as a control. Inocula and honey preparations were 
mixed in 35mm Petri dishes in a 1:1 ratio to a final culture volume of 2 ml and incubated for 
24 h at 37
oC with gentle shaking (80 rpm) in a microaerophilic environment. Growth was 
measured as an increase in A570nm and the remaining viable count was determined by plating 
a dilution series to Brucella agar + 2.5% FCS. 
 
Time course experiments 
For  assay  of  antibacterial  activity  over  time  Manuka  Honey  with  CycloPower
TM  was 
compared to matched uncomplexed MGO™ Manuka honey at 2% w (honey solids)/v and 
tested for  growth  inhibition  over time against  S. aureus,  MRSA and  P. aeruginosa. The 
concentration chosen was expected to give some growth, at least for the Manuka honey, and 
to be in the concentration window where if the form of honey used affected antimicrobial 
activity this would be apparent.  Growth was measured as increasing absorbance at 600 nm at 
regular time intervals to capture any impact upon the exponential growth of bacteria in the 
presence of Manuka honey and Manuka Honey with CycloPower
TM. To illustrate differences 
across the many samples tested “area under the curve” measurements (GraphPad Prism 5.02, 
GraphPad  Software,  San  Diego,  USA)  were  made  for  each  growth  curve  using  the 
exponential  region  of  the  no-additive  control  as  a  reference.  Data  was  transformed  to 
represent a percentage of the area under the curve of the no-additive control, which was set at 
100%.  
 
Statistical Analysis 
All assays were carried out at least in triplicate. Statistical analyses were performed using 
GraphPad Prism 5.02. Normality of data was tested by use of the D’Agostino & Pearson 
omnibus normality test. Differences in AUC were assessed by use of the non-parametric one-
tailed Mann-Whitney test to compare the antibacterial activity of Manuka honey and Manuka 
Honey with CycloPower
TM treatments. A p value  < 0.05 was taken as significant in all cases. 
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RESULTS 
MIC and MBC Results 
The MIC and MBC values of Manuka Honey and Manuka honey with Cyclopower™ are 
presented in Table 1. The results demonstrated that all four methylglyoxal honeys (100, 250, 
400 and 550) were capable of total inhibition of growth with ≤10% solutions for the majority 
of  organisms  tested.  Complexation  of  Manuka  honey  with  -cyclodextrin  did  not 
compromise  the  antibacterial  activity,  and  in  some  cases  showed  an  improved  in  vitro 
bacteriostatic  and/or  bactericidal  activity  (refer  to  Table  1).  Control  experiments  with  -
cyclodextrin alone showed no inhibitory activity at concentrations up to the equivalent of that 
present in a Manuka honey with CycloPower
TM solution with 30% honey solids by weight 
(36.7% w/v -cyclodextrin by weight). Growth of S. aureus was measured as total viable 
count at 4h and 24h indicating no short term bacteriostatic or longer term inhibitory activities 
were apparent.  
 
Table 1. The MIC and MBC for manuka honey and Manuka Honey with CycloPower
TM 
against a range of bacterial species 
 
  100H
1  100CP  250H  250CP  400H  400CP  550H  550CP 
 
2MIC 
Staphylococcus 
aureus  10  8  10  8  8  8  8  8 
Streptococcus 
pyogenes  8  6  8  2  6  2  4  2 
Pseudomonas 
aeruginosa  >10
3  >10  >10
  >10  >10  >10  >10  >10 
Moraxella 
catarrhalis  4  4  10  3  6  2  5  2 
Enterobacter 
aerogenes  >10
  >10  >10
  >10  >10  >10  >10  >10 
Helicobacter 
pylori  nd
4  nd  >4
5  <2  4  <2  4  <2 
5MBC 
Staphylococcus 
aureus  10  8  >10  10  8  8  8  8 
Streptococcus 
pyogenes  8  6  8  4  8  4  6  4 
Pseudomonas 
aeruginosa  >10
  >10  >10  >10  >10  >10  >10  >10 
Moraxella 
catarrhalis  10  8  10  8  8  8  8  4 
Enterobacter 
aerogenes  >10
  >10  >10
  >10  >10  >10  >10  >10 
 Helicobacter 
pylori  nd  nd  >4  4  >4  4  4  <2 
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Note 
1Number  denotes  MGO  level,  H  denotes  manuka  honey,  CP  denotes  Manuka 
Honey with CycloPower
TM manuka honey. 
2MICs tested between 2 and 10% honey solids per 
volume, except see
5. Values obtained were consistent across at least three assays. 
310% honey 
solids per volume was the highest concentration. 
4H. pylori was only tested at 2 and 4% 
honey solids per volume. 
4nd = Precipitation in CycloPower
TM manuka honey tests, probably 
due to serum in the media, did not allow measurement of MIC
5 MBCs tested between 2 and 
10% honey solids per volume, except see
5. Values obtained were consistent across all wells. 
Neither preparation was able to inhibit the growth of E. aerogenes at concentrations up 
to 10% honey solids by weight. The experiment was repeated on three separate occasions, in 
both microplate and 2 ml culture formats with the same result, and streak plates on horse 
blood  agar  from  cultures  grown  in  the  MIC  test  isolated  a  single  colony  type 
indistinguishable  from  E.  aerogenes  ATCC  13048  on  MacConkey  and  EMB  agars.  The 
resistance of species of Enterobacter to Manuka honey has been demonstrated previously
 
[14]. 
For H. pylori Manuka Honey with CycloPower
TM resulted in 100% bacterial inhibition at 
2 and 4% w (honey solids)/v, whereas the Manuka honey demonstrated full inhibition only 
for MGO400 and MGO550 honeys at 4% w (honey solids)/v. Plating of the hour incubation 
samples to Brucella agar + FCS showed that all three Manuka honey treatments (MGO250, 
400 and 550) at 2% w (honey solids)/v, and two treatments at 4% w/v (MGO250, and 400) 
were bacteriostatic only. In contrast, the Manuka Honey with CycloPower
TM preparations 
were all bactericidal at 4% w/v, as was the MGO550 Manuka honey sample.  
 
Time Course Experiments 
As MIC and MBC measure an endpoint, the effect of Cyclopower
TM on the bacteriostatic 
duration at sub-lethal concentrations was also assessed over time (refer Table 2).  
 
Table 2. Enhancement of the bacteriostatic duration with Manuka honey with Cyclopower
TM 
 
Methylglyoxal  Content 
(mg/kg)
a 
Growth in presence of Honey 
(mean ± S.D).
b 
Growth in Presence of honey with 
Cyclopower
TM (mean ± S.D).
 b 
Staphylococcus aureus 
250  79.5 (1.9)  47.2 (3.2)
c 
400  36.7 (15.3)  22.7 (2.5)
 c 
550  18.9 (9.8)  11.7 (2.0) 
MRSA 
250  78.5 (4.4)  55.3 (4.0)
 c 
400  50.5 (8.8)  28.5 (3.4)
 c 
550  32.3 (4.8)  22.2 (1.4)
 c 
Pseudomonas aeruginosa 
250  96.6 (1.7)  64.1 (6.0)
 c 
400  90.3 (6.7)  69.5 (9.0)
 c 
550  91.9 (2.7)  61.2 (7.7)
 c 
 
a.Matched (uncomplexed) honey or honey with Cyclopower
TM was added to BHI at 2% honey 
solids by weight.  
b.Growth, as area under the curve, is represented as a percentage of the no-additive control 
over the same time period. N=5. 
c.A significant reduction in growth with honey with Cyclopower
TM compared to uncomplexed 
honey (determined using a one tailed Mann-Whitney test; p<0.05). Functional Foods in Health and Disease 2014; 4(5):172-181                                                      Page 178 of 181 
Cyclopower
TM treatments gave a significantly greater reduction in growth compared with the 
matched uncomplexed MGO™ honey, suggesting that it increases the bacteriostatic duration 
at sub-lethal concentrations when compared to honey matched for methylglyoxal content. 
Only the S. aureus treatment with 2% MGO550 honey failed to demonstrate a significant 
reduction in growth, where the reduction due to honey itself was sufficiently large as to 
preclude further significant reduction due to the Cyclopower
TM. 
 
DISCUSSION 
The  results  of  this  study  have  demonstrated  that  Manuka  honey  exhibits  a  potent 
antimicrobial effect at methylglyoxal concentrations of 100–550 mg/kg, and these data align 
with results observed with Manuka honey in other studies, despite the fact that a range of 
methodologies have been employed [28-32]. Further, these results can likely be contributed 
directly  to  the  methylglyoxal  content  of  the  honeys  as  any  peroxide  factors  had  been 
eliminated by the addition of catalase to the assay, and it has been reported elsewhere that 
methylglyoxal is the primary antimicrobial agent in Manuka honey [28].
    
Importantly, the complexation of Manuka honey with -cyclodextrin does not appear to 
compromise the antibacterial efficacy when matched for percent honey solids, and in some 
cases it resulted in an enhanced action. Currently there is little data available describing the 
biochemical  action  of  Manuka  honey  with  CycloPower;  however,  we  suggest  that  the 
improved antibacterial action may be a result of a slow release of antimicrobial components 
to maintain a bacteriostatic concentration over an extended time period. This is a common 
property  associated  with  the  binding  of  molecules  into  a    -cyclodextrin  complex  [22], 
although  it  is  also  possible  that  the  -cyclodextrin  may  be  able  to  deliver  antimicrobial 
components to the bacterium allowing more efficient killing. Data from the present study 
-cyclodextrin  at  concentrations  of  up  to  36.7%  w/v  did  not  show  any 
antibacterial inhibition, and this agrees with well diffusion assays carried out with the same 
samples (J. Ketel, personal communication). Thus, a direct inhibitory role of -cyclodextrin 
is unlikely, though a synergistic action between this and other compounds in the Manuka 
honey  cannot  be  ruled  out.  Clearly,  the  chemistry  of  Manuka  honey  and  methylglyoxal 
complexation  with  -cyclodextrin,  and  the  specific  mechanism  of  the  enhancement  of 
antimicrobial  activity  demonstrated  for  Manuka  Honey  with  CycloPower
TM  are  areas  for 
further research. 
 Both the Manuka honey and the Manuka honey with CycloPower™ preparations have 
shown differing results on different organisms. P. aeruginosa and E. aerogenes, in particular, 
appeared  to  be  particularly  resistant  to  both  treatments  at  concentrations  of  up  to  10%, 
irrespective of methylgloxal content, though this does agree with previous studies [14, 15]. In 
contrast, S. aureus, S. pyogenes and H. pylori seem to exhibit relative sensitivity to Manuka 
honey. Jenkins et al. (2011)
 [30] indicated that Manuka honey can inhibit cell division via 
interaction of methylgloxal with atl, a gene coding for murein hydrolase, a peptidoglycan-
degrading enzyme implicated in cell separation. It is possible that the different degrees of 
inhibition seen by different organisms interacting with Manuka honey treatments could be 
due to differences in this process, however, this needs to be investigated further. 
 The treatment of gastrointestinal infections (including H. pylori gastritis and diarrhoeal 
diseases) is an attractive target for Manuka honey given by the oral route [31, 32], and it has 
been  described  as  part  of  an  effective  treatment  for  H.  pylori  [33].  In  addition,  the 
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methylglyoxal  is  not  stable  in  digestive  fluids
  [20,  34]  and  so  delivery  of  the  active 
components of honey to the intestines in a protected slow release form is desirable. This 
study  has  shown  that  the  antibacterial  activity  of  Manuka  honey  is  retained  (and  often 
enhanced)  when  complexed  with  -cyclodextrin  and  this  offers  potential  for  improved 
delivery options of Manuka honey to the GI tract. It is known that a-cyclodextrin is poorly 
digested and can transit through to the lower gut intact [21]; thus by complexing Manuka 
honey with the cyclodextrin it is proposed that the bioactive components of Manuka honey 
can be delivered to the necessary sites of actions. Further research is  clearly required to 
investigate the delivery of methylglyoxal by -cyclodextrin in the human GI tract, as well as 
the  antibacterial  performance  of  Manuka  Honey  with  CycloPower
TM  in  models  of 
gastrointestinal  infection  (including  testing  against  common  intestinal  pathogens  such  as 
Salmonella  spp.,  Shigella  spp.,  enteropathogenic  E.  coli  and  other  true  pathogens  of  the 
human gut).  
In conclusion, we show that Manuka Honey with CycloPower
TM, a Manuka honey in 
complex  with  cyclodextrin  retains  antibacterial  activity,  and  exhibits  enhanced 
bacteriostatic  and  possibly  bactericidal  activity  against  Gram-negative  and  Gram-positive 
pathogens. The combination of Manuka honey with  -cyclodextrin produces an easier to 
handle material that may facilitate a wider range of Manuka honey based products. Moreover, 
the combination of the  antibacterial  properties  of Manuka honey  and the complementary 
bioactive properties of -cyclodextrin may afford controlled release and delivery that could 
be suitable for intestinal infections. 
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